跳至主要内容
临床试验/ISRCTN15668391
ISRCTN15668391进行中(未招募)3 期

High-dose oral rifampicin to improve survival from adult tuberculous meningitis: a double-blinded randomised placebo-controlled Phase III trial

Makerere College of Health Sciences0 个研究点目标入组 500 人开始时间: 2019年6月17日最近更新:
适应症

试验速览

阶段
3 期
状态
进行中(未招募)
发起方
入组人数
500

研究概览

简要总结

2020 Protocol article in https://pubmed.ncbi.nlm.nih.gov/33083560/ protocol (added 23/10/2020)

研究设计

研究类型
Interventional

入排标准

性别
All

入选标准

  • •1. First episode TBM suspected by attending physician (>3 days of meningitis symptoms and CSF abnormalities) and anti-TB treatment planned
  • •2. Age =18 years
  • •3. Provision of written informed consent by participant or surrogate

排除标准

  • •1. Presence of jaundice, known liver cirrhosis, or known elevated ALT >5x ULN
  • •2. More than 5 doses of any TB treatment received within the previous 7 days
  • •3. Known allergy to: isoniazid, rifampicin, ethambutol, or pyrazinamide
  • •4. Known current/previous rifampicin-resistant M.tb infection
  • •5. Additional active and confirmed CNS infection
  • •6. Corticosteroids contraindicated
  • •7. Cannot or unlikely to attend regular clinic visits
  • •8. Pregnancy or breastfeeding
  • •9. Known renal failure with eGFR <30 ml/min by Modification of Diet in Renal Disease (MDRD) Study equation
  • •10. HIV Protease Inhibitor ongoing use

研究者

发起方
Makerere College of Health Sciences

相似试验